Caribou Biosciences Inc.

NAS: CRBU

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 30, 2023, 10:44 a.m.

/zigman2/quotes/228313444/composite

$

7.10

Change

-0.19 -2.61%

Volume

Volume 188,674

Real time quotes

/zigman2/quotes/228313444/composite

Previous close

$ 7.29

$ 7.10

Change

-0.19 -2.61%

Day low

Day high

$7.01

$7.29

Open

52 week low

52 week high

$4.89

$13.19

Open

Insider Actions for Caribou Biosciences Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/02/2022 Steven B. Kanner
Chief Scientific Officer
21,401   Derivative/Non-derivative trans. at $2.69 per share. 57,568
10/06/2022 Ryan Fischesser
VP of Finance and Controller
2,839   Derivative/Non-derivative trans. at $4.11 per share. 11,668
10/06/2022 Ryan Fischesser
VP of Finance and Controller
2,839   Derivative/Non-derivative trans. at $2.69 per share. 7,636
10/06/2022 Ryan Fischesser
VP of Finance and Controller
10,000   Disposition at $10.8 per share. 108,000
09/15/2022 Barbara G. McClung
Chief Legal Officer
27,518   Derivative/Non-derivative trans. at $2.69 per share. 74,023
09/15/2022 Barbara G. McClung
Chief Legal Officer
77   Derivative/Non-derivative trans. at $2.69 per share. 207
08/25/2022 Steven B. Kanner
Chief Scientific Officer
43,248   Disposition at $11.22 per share. 485,242
08/25/2022 Steven B. Kanner
Chief Scientific Officer
43,248   Derivative/Non-derivative trans. at $2.69 per share. 116,337
08/22/2022 Ryan Fischesser
VP of Finance and Controller
4,848   Award at $0 per share. 0
05/13/2022 Steven B. Kanner
Chief Scientific Officer
6,114   Derivative/Non-derivative trans. at $2.69 per share. 16,446
05/13/2022 Steven B. Kanner
Chief Scientific Officer
68,306   Derivative/Non-derivative trans. at $1.81 per share. 123,633
05/09/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/04/2022 Steven B. Kanner
Chief Scientific Officer
1,549   Derivative/Non-derivative trans. at $4.11 per share. 6,366
03/04/2022 Steven B. Kanner
Chief Scientific Officer
9,171   Derivative/Non-derivative trans. at $2.69 per share. 24,669

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
1 Purchases
0 Sales
21,401
0
Last 6 months
7 Purchases
2 Sales
102,770
53,248
Last 12 months
17 Purchases
2 Sales
226,794
53,248

Officers and Executives

Dr. Rachel E. Haurwitz
President, Chief Executive Officer & Director
Mr. Jason O’Byrne
Chief Financial Officer
Dr. Steven B. Kanner
Chief Scientific Officer
Ms. Cherry T. Thomas
Senior Vice President-Clinical Development
Dr. Syed Rizvi
Chief Medical Officer
Ms. Ruhi Khan
Chief Business Officer
Mr. Andrew L. Guggenhime
Director
Dr. Scott N. Braunstein
Director
Dr. Nancy C. Whiting
Director
Ms. Ran Zheng
Director
Dr. Dara Richardson-Heron
Director
Mr. David L. Johnson
Director
Dr. Natalie R. Sacks
Director
Mr. Ryan Fischesser
Vice President-Finance & Controller
Ms. Cindy Hayashi
Vice President-Human Resources
Ms. Barbara G. McClung
Secretary & Chief Legal Officer
Ms. Elaine Alambra
VP-Regulatory Affairs & Quality Assurance
Link to MarketWatch's Slice.